Recent Advances in Breast Cancer Diagnosis, Treatment, Psychology, Management, and Reconstruction

Den, Jennifer; Sisti, Andrea

doi:10.3390/medicina59020212

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer is the most common malignant tumor in women and one of the main causes of disease burden worldwide (1). Despite the significant advances in diagnosis and prognosis, treating patients with advanced stages remains challenging (2)(3)(4)(5). To improve the prognosis, early detection, and timely treatment are of great significance.…”

Section: Introductionmentioning

confidence: 99%

GLS as a diagnostic biomarker in breast cancer: in-silico, in-situ, and in-vitro insights

Zhang,

Wang,

Huang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundRecently, a novel programmed cell death mechanism, Cuproptosis, has been discovered and found to play an important role in the development and progression of diverse tumors. In the present study, we comprehensively investigated the core gene of this mechanism, GLS, in breast cancer.Materials and methodsBulk RNA sequencing data were curated from the TCGA repository to investigate the aberrant expression of GLS over diverse cancer types. Then, we examined its efficacy as a diagnostic biomarker in breast cancer by Area Under Curve (AUC) of the Receiver Operative Characteristic (ROC) curve. Furthermore, by applying siRNA technique, we knocked down the GLS expression level in cancerous cell lines, measuring the corresponding effects on cell proliferation and metastasis. Afterward, we explored the potential implications of GLS expression in the tumor immune microenvironment quantitatively by using several R packages and algorithms, including ESTIMATE, CIBERSORT, etc.ResultsPan-cancer analysis suggested that GLS was aberrantly over-expressed in many cancer types, with breast cancer being typical. More in-depth analyses revealed the expression of GLS exerted a high ROC-AUC value in breast cancer diagnosis. Through the knock-down of GLS expression, it was found that GLS expression was strongly relevant to the growth and metastasis of tumor. Furthermore, it was also found to be correlated with the immune tumor microenvironment.ConclusionWe highlighted that GLS expression might be applicable as a diagnostic biomarker in breast cancer and possess significant implications in the growth and metastasis of tumor and the immune tumor microenvironment, sharing new insights into ontological and personalized medicine.

show abstract

Section: Introductionmentioning

confidence: 99%

GLS as a diagnostic biomarker in breast cancer: in-silico, in-situ, and in-vitro insights

Zhang,

Wang,

Huang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Recent Advances in Breast Cancer Diagnosis, Treatment, Psychology, Management, and Reconstruction

Abstract: Breast cancer is the second most common cancer in women after skin cancer [...]

Cited by 1 publication

References 6 publications

GLS as a diagnostic biomarker in breast cancer: in-silico, in-situ, and in-vitro insights

GLS as a diagnostic biomarker in breast cancer: in-silico, in-situ, and in-vitro insights

Contact Info

Product

Resources

About